DefinePK

Abstract

The rise of fungal resistance in dermatology poses a significant threat to public health, compromising our ability to effectively treat common skin infections. As dermatologists, researchers, and policymakers, it is imperative that we acknowledge the severity of this issue and take collective action to mitigate its con-sequences.
      Fungal infections, such as dermatophytosis, candidiasis, and onychomycosis, affect millions of people worldwide. Traditionally, these infections have been treated with topical or systemic antifungal agents, such as azoles, allylamines, and polyenes. However, the overuse and misuse of these medications have accelerated the deve-lopment of fungal resistance, rendering them less effective.
            The consequences of fungal resistance are far-reaching. Patients may experience prolonged, recurrent, and severe infections, increased mor-bidity, transmission of infection, and reduced quality of life. Moreover, the economic burden of fungal resistance is substantial, with estimated annual costs exceeding billions of dollars